Displaying drugs 2901 - 2925 of 3951 in total
BNT-162A1
BNT-162A1 is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
Investigational
Matched Categories: … Recombinant Proteins …
OC-1012
OC-1012 is a compound which has emerged as a promising therapeutic agent for the treatment and prevention of mucositis, a serious side effect of chemotherapy and head and neck radiation therapy.
Investigational
TAS-108
Investigational
ANZ-100
Investigational
AZX-100
Investigational
TAS-106
TAS-106 is a new nucleoside antimetabolite. TAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours .
Investigational
Matched Description: … -106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human …
TAS-102
TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine. Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil...
Investigational
LSZ-102
LSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).
Investigational
MYR-101
MYR-101 (rAAV-Olig001-ASPA) is a recombinant adeno-associated virus (rAAV) vector-based gene therapy intended to treat Canavan disease. Canavan disease is a fatal childhood genetic disorder characterized by white matter degeneration in the brain. It is caused by a mutation in the aspartoacylase gene (ASPA), which leads to a deficiency of the...
Investigational
Matched Description: … MYR-101 (rAAV-Olig001-ASPA) is a recombinant adeno-associated virus (rAAV) vector-based gene therapy …
SBT-100
SBT-100 is an anti-signal transducer and activator of transcription 3 (STAT3) B VHH13 single-domain antibody (sdAb). It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136]
Investigational
SUN-101
Investigational
TTI-101
Investigational
DYN-101
DYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.
Investigational
AVS-100
Investigational
NGN-101
NGN-101 is an adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 gene
Investigational
Matched Description: … NGN-101 is an adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 …
CTR-107
CTR-107 is a synthetic targeted growth factor. It is being investigated for the treatment of familial exudative vitreoretinopathy.
Investigational
LMB-100
LMB-100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity.
Investigational
Aspartame
Flavoring agent sweeter than sugar, metabolized as phenylalanine and aspartic acid.
Investigational
Nutraceutical
Matched Products: … ASTAT 10 MG TABLET, 100 ADET ... ASTAT 10 MG TABLET, 300 ADET ... UNOTAT 10 MG TABLET, 100 ADET …
Lumiflavin
Experimental
LJP 1082
LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1. LJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis. Antibody-mediated thrombosis, also called antiphospholipid syndrome (APS), is a blood...
Investigational
NCX 1015
NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.
Investigational
ETC-1001
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
Displaying drugs 2901 - 2925 of 3951 in total